Halozyme Therapeutics Investor Relations Material

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes novel oncology therapies in the United States and internationally. Its human enzymes are based on intellectual property covering the family of human enzymes known as hyaluronidases. The company operates in two segments, Enhanze Technology, and Clinical Development Pipeline Products. The Enhanze Technology segment engages in the research and development of product candidates that use its proprietary technology platform to develop subcutaneous formulations of injectable biologics.